Jordan M Schecter, MD is currently the Vice President for Cellular Therapy at Janssen (the Pharmaceutical Company of Johnson & Johnson). In this role, he is the global clinical leader for Ciltacabtagene Autoleucel (an experimental CAR-T therapy being developed for Multiple Myeloma). Previous to this role, Dr Schecter was the co-Clinical lead for Daratumumab (Darzalex ®), a monoclonal antibody first approved in 2015 for the treatment of multiple myeloma. Prior to joining Janssen, Dr Schecter was an associate professor of medicine at Columbia University Medical Center in New York City where he was involved in clinical research for multiple myeloma and Amyloidosis. He earned his MD at Warren Alpert Medical School and completed his internship at Rhode Island Hospital, both at Brown University and completed his residency and a fellowship in medical haematology and oncology at Columbia University Medical Center.